| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
AzacitidineDNA (Methylation)5 Aza 2 deoxycytidineMyelodysplastic syndromeDecitabineLenalidomideLeukemia (acute myeloic)Leukemia (chronic myelomonocytic leukaemia)| 1 | 2005 | FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. | 
| + | - | nl | Oncologist 10(3):176-82 (2005) |
| 2 | 2002 | 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. |
| + | - | nl | Oncogene 21(35):5483-95 (2002) |
| 3 | 2010 | 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. | 
| + | - | nl | Haematologica 95(2):303-10 (2010) |
| 4 | 2010 | Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. |
| + | - | nl | Haematologica 95(2):340-2; author reply 343-4 (2010) |
| 5 | 2010 | How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes. |
| + | - | nl | Hematology Am Soc Hematol Educ Program 2010(-):314-21 (2010) |
| 6 | 2010 | Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. |
| + | - | nl | Health Technol Assess 14 Suppl 1(-):69-74 (2010) |
